1. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study
- Author
-
Makoto Kajizono, Toshiaki Sendo, Yoshihiko Soga, Yuhko Sugiura, Hikaru Sada, Junji Matsuoka, and Yoshihisa Kitamura
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Osteoporosis ,Pharmaceutical Science ,Zoledronic Acid ,Diabetes Complications ,Risk Factors ,Neoplasms ,Internal medicine ,Odds Ratio ,medicine ,Humans ,Dental Care ,Aged ,Retrospective Studies ,Pharmacology ,Bone Density Conservation Agents ,Diphosphonates ,business.industry ,Incidence ,Imidazoles ,Osteonecrosis ,Cancer ,Anemia ,Retrospective cohort study ,General Medicine ,Odds ratio ,Middle Aged ,Bisphosphonate ,medicine.disease ,Surgery ,Logistic Models ,Zoledronic acid ,Denosumab ,Jaw ,Female ,Bone Diseases ,business ,Osteonecrosis of the jaw ,medicine.drug - Abstract
Zoledronic acid and denosumab are two antiresorptive drugs currently in use for treating osteoporosis. They have different mechanisms of action, but both have been shown to delay the onset of skeletal-related events in patients with advanced cancer. However, medication-related osteonecrosis of the jaw (MRONJ) has been reported in cancer patients treated with zoledronic acid or denosumab. We studied 155 patients with several types of advanced cancer who were treated with zoledronic acid or denosumab in our hospital during the period from April 2010 through March 2013. Thirteen of these 155 patients (8.4%) developed MRONJ. MRONJ development was significantly associated with the number of zoledronic acid or denosumab infusions (p
- Published
- 2015
- Full Text
- View/download PDF